Home  »  Finance   »  Moderna Inc. (MRNA) Is A Good Stock To Invest In...

Moderna Inc. (MRNA) Is A Good Stock To Invest In

Moderna Inc. (NASDAQ:MRNA) concluded the trading at $176.81 on Wednesday, November 23 with a fall of -1.55% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $179.59 and 5Y monthly beta was reading 1.69 with its price kept floating in the range of $174.58 and $179.36 on the day. Company’s P/E ratio for the trailing 12 months is 6.39. Considering stock’s 52-week price range provides that MRNA hit a high price of $376.65 and saw its price falling to a low level of $115.03 during that period. Over a period of past 1-month, stock came adding 29.46% in its value.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


With its current market valuation of $68.79 billion, Moderna Inc. is set to declare its quarterly results on Feb 22, 2023 – Feb 27, 2023. Analysts are in estimates of $3.29 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $25.6 for 2022 with estimates of that growing to $8.66 in next year. These estimates are suggesting current year growth of -9.50% for EPS and -66.20% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $3.53 billion. They suggested that in the process company could generate revenue of as low as $2.52 billion which could climb up to $4.7 billion to hit a high. The average estimate is representing a decrease of -43.20% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $21.31 billion in 2022, which will be 15.40% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review MRNA stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 100% Buy for it.

Digging deeper we become aware of the PEG ratio of the MRNA stock which is currently positioned at 0. It further provides that stock’s current price level is 7.17% away from its 20-day simple moving average and is 24.20% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 64.36 while volatility remained at 3.72% over the past week which changes to 5.57% when measuring it over the past month. Beta is valued at 1.74, while measure of average true range or ATR is currently at 8.47. In predicting price targets of as low as $101.00 and as high as $506.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $213.71. Stock’s current price level is 42.88% above from estimated low price target while it is -186.18% below the estimated high; and even if the MRNA’s share succeeded to reach the median price of $185.50, then the outlook of -4.91% could come to the excitement of the investors.

In comparing Moderna Inc. (MRNA)’s stock with other industry players reveals that stock’s current price change of -1.55% and that of -36.03% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price raised by 0.11% in the last trading and went through an increase of 10.16% in past 12-month trading. Industry’s another major player Pfizer Inc. (PFE) has fall -0.47% down in previous session, but over the past year has faced a fall of -4.37% over the same period. Moderna Inc. has a P/E ratio of 6.39 against that of Johnson & Johnson’s 24.64 while Pfizer Inc. is showing 9.27 for the same. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.

Having a second look at Moderna Inc. (NASDAQ:MRNA) provides that stock’s average daily trading volume for 3 months was 4.88 million, while it jumped to 4.0 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 390.00 million.

The percentage of outstanding shares held by the insiders is 2.50% while it is 66.00% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 16.16 million which implies a short ratio of 3.08. This shows down a 4.13% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 16.34 million in the previous month. Subtraction of -30.38% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *